JAMES B. BREITMEYER - 20 Jan 2022 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
20 Jan 2022
Net transactions value
$0
Form type
4
Filing time
24 Jan 2022, 15:14:57 UTC
Previous filing
05 Jan 2022
Next filing
31 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONCT Stock Option Award $0 +637,000 $0.000000 637,000 20 Jan 2022 Common Stock 637,000 $1.94 Direct F1
transaction ONCT Stock Option Award $0 +165,000 $0.000000 165,000 20 Jan 2022 Common Stock 165,000 $1.94 By Spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in 36 equal monthly installments over the three-year period thereafter, subject to the Recipient's continued employment or service with the Issuer on each such date.